|Bid||15.921 x 33800|
|Ask||16.354 x 33100|
|Day's range||15.896 - 16.186|
|52-week range||7.103 - 23.857|
|PE ratio (TTM)||-10.85|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||N/A|
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Omeros Corporation shares surged as much as 10% in morning trade Thursday, before paring some gains, after the company announced a settlement with Endo International PLC's Par Pharmaceutical Inc. that ...